Table 1.
Descriptive Statistics
| Variable | First Study: DXA Imaging (n = 257) | Second Study: SE Imaging (n = 173) |
|---|---|---|
| Sex, female/male, no. (%) | 238/19 (93/7) | 166/7 (96/4) |
| Age, y, mean (SD) | 72.2 (8.8) | 69.1 (10.1) |
| Lumbar 1 to 4, T score, mean (SD) | −2.08 (1.11) | −1.93 (1.20) |
| Femur neck, T score, mean (SD) | −2.02 (0.78) | −1.84 (0.89)a |
| Hip, T score, mean (SD) | −1.56 (0.89) | −1.35 (0.95)a |
| Treatment, y, mean (SD) | 7.6 (2.7) | 6.8 (2.5)a |
| Bisphosphonates, no. (%) | ||
| Alendronate | 170 (66.3) | 111 (64.2) |
| Risedronate | 59 (23.0) | 29 (16.8) |
| Ibandronate | 24 (9.3) | 33 (19.1) |
| Zoledronate | 3 (1.2) | 0 (0) |
| Etidronate | 1 (0.4) | 0 (0) |
| DXA-suspected AFF, no. (%) | 19 (7.4) | 12 (6.9) |
| X-ray findings, no. (%) | ||
| Normal | 7 (2.7) | 6 (3.5) |
| Abnormal: non-AFF | 5 (2.0) | 6 (3.5) |
| Abnormal: AFF | 7 (2.7) | 0 (0) |
Abbreviation: SD, standard deviation.
a
Significant difference (P < 0.05) between groups as per independent t test.